|
Products 
Lipolysis Injection
Lipolysis Injection Lose Weight Removal Fat Ozempik Saxendas Semaglutide Injection 1.5ml 3ml 4mg Online Sale
Available
631
| Name | Value |
|---|---|
| color | red |
| 1 | 65 |
| 1box | 5vials*10ml |
| 10vials | 1box |
| Place of Origin | Seoul, South Korea |
| Brand Name | Deolipo(Kabelline) |
| Model Number | DC100 |
| Operation System | Deoxycholic acid |
| Type | Other |
| Feature | Face Lift, Cellulite Reduction, Weight Loss |
| Application | For Commercial |
| Keywords | Deoxycholic acid for double chine |
| Function | Face contour, body lipolysis |
| Material | Deoxycholic acid |
| Specification | 5vials*10ml |
| delivery time | 3-7 working days |
| payment method | Credit Card Apple Pay Bank Transfer |
| Delivery conditions | DAP |
| Lemon Bottle | 115 |
| Origin | South Korea |
| Semaglutide can reduces hunger, food craving and body fat. | |
| Discribe | Semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogues. Semaglutide is a long-acting dosage form based on the basic structure of liraglutide, which is more effective in the treatment of type 2 diabetes mellitus. Compared with lilarlutide, somalutide has a longer aliphobic chain and an increased hydrophobicity, but somalutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced.PEG modification can not only tightly bind to albumin, cover up the DPP-4 enzymatic hydrolysis site, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation. Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug. Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity. It reduces hunger, food craving and body fat. |
